A Phase 2/3 interventional study of Axitinib and Sandostatin LAR in Neuroendocrine Tumors and Advanced Cancer, sponsored by Grupo Espanol de Tumores Neuroendocrinos. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Grupo Espanol de Tumores Neuroendocrinos · Phase 2/3, Interventional, and Treatment
Assess whether therapy with axitinib, a potent angiogenic inhibitor of the tyrosine kinase receptors of VEGF bioavailable by oral administration, is capable of improving PFS in patients with advanced G1-G2 NETs of nonpancreatic origin with progressive disease documented in the 12 months prior to entering the study.
Phase II/III, prospective, multicenter, randomized (1:1), double-blind study to evaluate the efficacy and tolerability of axitinib in patients diagnosed with advanced G1-G2 neuroendocrine tumors (WHO 2010) of nonpancreatic origin that have presented documented disease progression in the 12 months prior to entering the study. In the first part of the study (Phase II), 105 patients were enrolled. The second part of the study is the expansion to Phase III, which is expected to include 148 additional patients. Patients will be randomized to receive Sandostatin LAR with axitinib or Sandostatin LAR with placebo until disease progression or unacceptable toxicity occurs. Randomization will be stratified by the time from diagnosis to enrollment in the study (more vs less than or equal to 12 months), the origin of the primary tumor (gastrointestinal tract vs non-gastrointestinal tract [lung or other sites]) and ki-67 (\< 5% vs > 5%).
Adequate organ function as defined by the following criteria:
Exclusion Criteria:
1. Subjects must be evaluated with regard to the following exclusion criteria:
Gastrointestinal abnormalities, including:
Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days
Drug: Axitinib · Drug: Sandostatin LAR
Placebo BID + Sandostatin LAR 30mg/28 days
Drug: Sandostatin LAR · Drug: Placebo
Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
Efficacy of Axitinib in Terms of PFS (Investigator Assessment)
Calculated from the date of random assignment until the date of first progressive disease or death, whichever occurs first. Progression of the disease was assessed by investigators using tumor imaging computed tomography scans and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 PFS was analysed by Kaplan-Meier method and compared with log-rank tests. Patients alive with no event at data cut off were censored on their last tumor assessment
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Objective Response Rate (ORR) (Investigator Assessment)
Measured changes in the sum of longest diameter of target lesions measured in mm according to RECIST 1.1 criteria. Assessed by investigators. Patients are categorized depending on the percentage of tumor redution: Complete response (CR): dissapearance of all lesions Partial response (PR): reduction \> 30% in the sum of longest diameter of target lesions Stable disease (SD): Tumor size betwee 30% reduction and 20% increase in the sum of longest diameter of target lesions Progressive disease (PD): increase \> 20% in the sum of longest diameter of target lesions ORR comprise all patients who achieved at least a CR or PR at any timepoint during follow-up.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Biochemical Response (5-OH-indoleacetic Acid and Chromogranin A)
measurable in mL/ 24h and ng/ml respectively, through blood and urine test in patients with baseline elevation of CgA or 5-HIAA levels. This endpoint measures the negativization of these two tumor biomarkers.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Safety and Tolerability of Axitinib (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE], Version 4.0)
All adverse events and serious adverse events will be monitored with regular monitoring of hematology and blood chemistry parameters and regular physical examinations. Adverse events will be evaluated continuously throughout the study. Safety and tolerability will be assessed according to the National Institute of Health/National Cancer Institute (NIH/NCI) Common Terminology Criteria for Adverse Events version 4 (CTCAE v4)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Efficacy of Axitinib in Terms of PFS (Central Blinded Assessment)
Calculated from the date of random assignment until the date of first progressive disease or death, whichever occurs first. Progression of the disease was assessed by central blinded reviewers using tumor imaging by computed tomography scans and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 PFS was analysed by Kaplan-Meier method and compared with log-rank tests. Patients alive with no event at data cut off were censored on their last tumor assessment
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Objective Response Rate (ORR) (Central Blinded Assessment)
Measured changes in the sum of longest diameter of target lesions measured in mm according to RECIST 1.1 criteria. Assessed by central blinded reviewers. Patients are categorized depending on the percentage of tumor redution: Complete response (CR): dissapearance of all lesions Partial response (PR): reduction \> 30% in the sum of longest diameter of target lesions Stable disease (SD): Tumor size betwee 30% reduction and 20% increase in the sum of longest diameter of target lesions Progressive disease (PD): increase \> 20% in the sum of longest diameter of target lesions ORR comprise all patients who achieved at least a CR or PR at any timepoint during follow-up.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Patients enrolled and randomized
| Milestone | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR |
|---|---|---|
| Started | 126 | 130 |
| Completed | 125 | 130 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Calculated from the date of random assignment until the date of first progressive disease or death, whichever occurs first. Progression of the disease was assessed by investigators using tumor imaging computed tomography scans and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 PFS was analysed by Kaplan-Meier method and compared with log-rank tests. Patients alive with no event at data cut off were censored on their last tumor assessment
| months | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR |
|---|---|---|
| Efficacy of Axitinib in Terms of PFS (Investigator Assessment) | 17.2 (13.6 to 24.7) | 13.1 (10.9 to 18.6) |
Measured changes in the sum of longest diameter of target lesions measured in mm according to RECIST 1.1 criteria. Assessed by investigators. Patients are categorized depending on the percentage of tumor redution: Complete response (CR): dissapearance of all lesions Partial response (PR): reduction \> 30% in the sum of longest diameter of target lesions Stable disease (SD): Tumor size betwee 30% reduction and 20% increase in the sum of longest diameter of target lesions Progressive disease (PD): increase \> 20% in the sum of longest diameter of target lesions ORR comprise all patients who achieved at least a CR or PR at any timepoint during follow-up.
| Participants | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR |
|---|---|---|
| Complete response | 2 | 1 |
| Partial response | 20 | 5 |
| Stable disease | 87 | 96 |
| Progressive disease | 9 | 25 |
| Not evaluable | 8 | 3 |
measurable in mL/ 24h and ng/ml respectively, through blood and urine test in patients with baseline elevation of CgA or 5-HIAA levels. This endpoint measures the negativization of these two tumor biomarkers.
| Participants | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR |
|---|---|---|
| CgA response — Response | 31 | 27 |
| CgA response — No response | 38 | 45 |
| 5-HIAA response — Response | 19 | 16 |
| 5-HIAA response — No response | 29 | 30 |
All adverse events and serious adverse events will be monitored with regular monitoring of hematology and blood chemistry parameters and regular physical examinations. Adverse events will be evaluated continuously throughout the study. Safety and tolerability will be assessed according to the National Institute of Health/National Cancer Institute (NIH/NCI) Common Terminology Criteria for Adverse Events version 4 (CTCAE v4)
| Participants | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR |
|---|---|---|
| Any grade AEs — Yes, reported events | 121 | 124 |
| Any grade AEs — No, no events reported | 4 | 6 |
| SAEs — Yes, reported events | 48 | 30 |
| SAEs — No, no events reported | 77 | 100 |
| Toxicities requiring end of treatment — Yes, reported events | 23 | 4 |
| Toxicities requiring end of treatment — No, no events reported | 102 | 126 |
| Toxicities requiring treatment temporary interruption — Yes, reported events | 76 | 55 |
| Toxicities requiring treatment temporary interruption — No, no events reported | 49 | 75 |
| Toxicities requiring dose reductions — Yes, reported events | 44 | 10 |
| Toxicities requiring dose reductions — No, no events reported | 81 | 120 |
Calculated from the date of random assignment until the date of first progressive disease or death, whichever occurs first. Progression of the disease was assessed by central blinded reviewers using tumor imaging by computed tomography scans and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 PFS was analysed by Kaplan-Meier method and compared with log-rank tests. Patients alive with no event at data cut off were censored on their last tumor assessment
| months | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR |
|---|---|---|
| Efficacy of Axitinib in Terms of PFS (Central Blinded Assessment) | 16.6 (13.5 to 24.2) | 9.9 (8.2 to 13.9) |
Measured changes in the sum of longest diameter of target lesions measured in mm according to RECIST 1.1 criteria. Assessed by central blinded reviewers. Patients are categorized depending on the percentage of tumor redution: Complete response (CR): dissapearance of all lesions Partial response (PR): reduction \> 30% in the sum of longest diameter of target lesions Stable disease (SD): Tumor size betwee 30% reduction and 20% increase in the sum of longest diameter of target lesions Progressive disease (PD): increase \> 20% in the sum of longest diameter of target lesions ORR comprise all patients who achieved at least a CR or PR at any timepoint during follow-up.
| Participants | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR |
|---|---|---|
| Complete response | 2 | 0 |
| Partial response | 13 | 4 |
| Stable disease | 98 | 109 |
| Progressive disease | 1 | 12 |
| Not evaluable | 3 | 1 |
Collected over Throughout study period, approximately 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib + Sandostatin LAR | 68/125 (54.4%) | 48/125 (38.4%) | 121/125 (96.8%) |
| Placebo + Sandostatin LAR | 48/130 (36.9%) | 30/130 (23.1%) | 124/130 (95.4%) |
| Event | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR |
|---|---|---|
| PyrexiaGeneral disorders | 0/125 | 4/130 |
| HyperbilirubinaemiaHepatobiliary disorders | 3/125 | 2/130 |
| DiarrheaGastrointestinal disorders | 3/125 | 0/130 |
| Intestinal obstructionGastrointestinal disorders | 3/125 | 3/130 |
| COVID-19Infections and infestations | 0/125 | 3/130 |
| Angina pectorisCardiac disorders | 2/125 | 0/130 |
| CholecystitisHepatobiliary disorders | 2/125 | 0/130 |
| Cholecystitis acuteHepatobiliary disorders | 2/125 | 0/130 |
| PyrexiaGeneral disorders | 2/125 | 1/130 |
| Acute coronary syndromeCardiac disorders | 2/125 | 0/130 |
| Event | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR |
|---|---|---|
| DiarrheaGastrointestinal disorders | 81/125 | 52/130 |
| HypertensionVascular disorders | 66/125 | 45/130 |
| AstheniaGeneral disorders | 66/125 | 45/130 |
| Mucosal inflammationGastrointestinal disorders | 37/125 | 17/130 |
| Decreased appetiteMetabolism and nutrition disorders | 33/125 | 16/130 |
| Palmar-plantar erythrodysesthesia syndromeSkin and subcutaneous tissue disorders | 25/125 | 4/130 |
| AphoniaNervous system disorders | 19/125 | 1/130 |
| DysphoniaNervous system disorders | 19/125 | 1/130 |
| NauseaGastrointestinal disorders | 18/125 | 17/130 |
| HeadacheNervous system disorders | 18/125 | 15/130 |
| Age, Continuous(years) | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR | Total |
|---|---|---|---|
| Median | 62 (21 to 85) | 60 (26 to 83) | 61 (21 to 85) |
| Sex: Female, Male(Participants) | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR | Total |
|---|---|---|---|
| Female | 55 | 63 | 118 |
| Male | 71 | 67 | 138 |
| Race and Ethnicity Not Collected(Participants) | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Eastern Cooperative Oncology Group performance status (ECOG-PS)(Participants) | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR | Total |
|---|---|---|---|
| Score 0 | 75 | 88 | 163 |
| Score 1 | 49 | 41 | 90 |
| Score 2 | 1 | 0 | 1 |
| Unknown | 1 | 1 | 2 |
| Tumor grade (WHO)(Participants) | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR | Total |
|---|---|---|---|
| Grade 1 | 32 | 46 | 78 |
| Grade 2 | 94 | 83 | 177 |
| Unknown | 0 | 1 | 1 |
| Ki-67(Participants) | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR | Total |
|---|---|---|---|
| ki-67 0-2 | 31 | 43 | 74 |
| ki-67 >2-5 | 45 | 39 | 84 |
| ki-67 >5 - 10 | 26 | 27 | 53 |
| ki-67 >10 - 20 | 23 | 19 | 42 |
| Not specified | 1 | 2 | 3 |
| Time from initial cancer diagnosis to study entry(Participants) | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR | Total |
|---|---|---|---|
| ≤ 12 months | 54 | 51 | 105 |
| > 12 months | 72 | 79 | 151 |
| Primary tumour location(Participants) | Axitinib + Sandostatin LAR | Placebo + Sandostatin LAR | Total |
|---|---|---|---|
| Lung | 38 | 34 | 72 |
| Gastric | 3 | 4 | 7 |
| Small intestine | 60 | 67 | 127 |
| Colorectal | 13 | 11 | 24 |
| Unknown primary | 9 | 7 | 16 |
| Other locations | 3 | 7 | 10 |
8 further baseline measures are reported on the registry.
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Grupo Espanol de Tumores Neuroendocrinos